NIH Ends Clinical Trial of Eli Lily's Coronavirus Antibody Therapy Candidate

Eric Volkman, The Motley Fool
·2 min read
NIH Ends Clinical Trial of Eli Lily's Coronavirus Antibody Therapy Candidate
NIH Ends Clinical Trial of Eli Lily's Coronavirus Antibody Therapy Candidate

LY-CoV555, which was being tested in combination with Gilead Sciences' remdesivir, showed no evidence of benefiting hospitalized COVID-19 patients.